Detalles de la búsqueda
1.
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
Diabetes Obes Metab
; 21(2): 293-302, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30187620
2.
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.
Diabetes Obes Metab
; 19(2): 162-171, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717222
3.
Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.
Diabetes Obes Metab
; 20(5): 1327-1328, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29316175
4.
Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.
BMC Med
; 10: 92, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22891821
5.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.
Front Psychiatry
; 9: 781, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30745885
6.
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.
BMJ Open
; 4(1): e004158, 2014 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24401727
7.
Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
Am J Psychiatry
; 170(6): 681-2, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23732970
Resultados
1 -
7
de 7
1
Próxima >
>>